Abstract
Mammalian neutral sphingomyelinase 2 is encoded by the gene smpd3 and belongs to the family of hydrolases which catalyze the breakdown of sphingomyelin to form ceramide and phosphocholine. The bioactive ceramide can then act as the second messenger molecule capable of mediating an array of cellular events, such as growth arrest and apoptosis. Recent studies have revealed that the expression and activity of neutral sphingomyelinase 2 are selectively regulated and this regulation can take place at the transcriptional level as well as at the post-translational level. Upon exposure to oxidative stress, endoplasmic reticulum stress, tumour necrosis factor alpha stimulation or anti-cancer drugs, altered neutral sphingomyelinase 2 activity directly translates into changes in ceramide levels which help cells mount an appropriate response. On the other hand, inappropriate activation or inhibition of neutral sphingomyelinase 2 could contribute to the development of pathological conditions such as cancer and endothelial dysfunction. In this chapter, we focus on current knowledge regarding neutral sphingomyelinase 2 structure, the regulation of its activity, its function and potential involvement in stress response and cancer genesis.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- APL:
-
Anionic phospholipid
- ATRA:
-
All-trans retinoic acid
- BAEC:
-
Bovine aortic endothelial cells
- EED:
-
Embryonic ectodermal development
- eNOS:
-
Endothelial nitric oxide synthase
- iNOS:
-
Inducible nitric oxide synthase
- nNOS:
-
Neuronal nitric oxide synthase
- ER:
-
Endoplasmic reticulum
- HAEC:
-
Human airway epithelial cells
- HEK:
-
Human embryonic kidney
- HSP:
-
Heat shock protein
- MAPK:
-
Mitogen activated protein kinase
- PKC:
-
Protein kinase C
- ROS:
-
Reactive oxygen species
- SM:
-
Sphingomyelin
- SMase:
-
Sphingomyelinase
- TNF:
-
Tumour necrosis factor
References
Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E, Kelly S, Allegood JC, Liu Y, Peng Q, Ramaraju H, Sullards MC, Cabot M, Merrill AH Jr. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta. 2006;1758:1864–84.
Morales A, Lee H, Goni FM, Kolesnick R, Fernandez-Checa JC. Sphingolipids and cell death. Apoptosis. Int J Programmed Cell Death. 2007;12:923–39.
Igarashi Y. Functional roles of sphingosine, sphingosine 1-phosphate, and methylsphingosines: in regard to membrane sphingolipid signaling pathways. J Biochem. 1997;122:1080–7.
O’Brien JS, Blankenhorn DH. Fatty acid composition of sphingomyelin and lecithin in normal human serum. Proc Soc Exp Biol Med. 1965;119:862–6.
Kishimoto Y, Agranoff BW, Radin NS, Burton RM. Comparison of the fatty acids of lipids of subcellular brain fractions. J Neurochem. 1969;16:397–404.
Koval M, Pagano RE. Intracellular transport and metabolism of sphingomyelin. Biochim Biophys Acta. 1991;1082:113–25.
Allan D, Kallen KJ. Transport of lipids to the plasma membrane in animal cells. Prog Lipid Res. 1993;32:195–219.
Hill PA, Tumber A. Ceramide-induced cell death/survival in murine osteoblasts. J Endocrinol. 2010;206:225–33.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.
Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J Biol Chem. 1994;269:3125–8.
Otterbach B, Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell. 1995;81:1053–61.
Schneider PB, Kennedy EP. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J Lipid Res. 1967;8:202–9.
Kirschnek S, Paris F, Weller M, Grassme H, Ferlinz K, Riehle A, Fuks Z, Kolesnick R, Gulbins E. CD95-miated apoptosis in vivo involves acid sphingomyelinase. J Biol Chem. 2000;275:27316–23.
Komatsu M, Takahashi T, Abe T, Takahashi I, Ida H, Takada G. Evidence for the association of ultraviolet-C and H(2)O(2)-induced apoptosis with acid sphingomyelinase activation. Biochim Biophys Acta. 2001;1533:47–54.
Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z, Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86:189–99.
Li X, Gulbins E, Zhang Y. Oxidative stress triggers Ca-dependent lysosome trafficking and activation of acid sphingomyelinase. Cell Physiol Biochem. 2012;30:815–26.
Smith EL, Schuchman EH. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J. 2008;22:3419–31.
Zeidan YH, Hannun YA. The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr Mol Med. 2010;10:454–66.
Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta. 2006;1761:281–91.
Duan RD, Nyberg L, Nilsson A. Alkaline sphingomyelinase activity in rat gastrointestinal tract: distribution and characteristics. Biochim Biophys Acta. 1995;1259:49–55.
Zhang Y, Cheng Y, Hansen GH, Niels-Christiansen LL, Koentgen F, Ohlsson L, Nilsson A, Duan RD. Crucial role of alkaline sphingomyelinase in sphingomyelin digestion: a study on enzyme knockout mice. J Lipid Res. 2011;52:771–81.
Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci U S A. 1998;95:3638–43.
Sawai H, Domae N, Nagan N, Hannun YA. Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C. J Biol Chem. 1999;274:38131–9.
Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem. 2006;281:13784–93.
Corcoran CA, He Q, Ponnusamy S, Ogretmen B, Huang Y, Sheikh MS. Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies. Mol Cancer Res. 2008;6:795–807.
Hofmann K, Tomiuk S, Wolff G, Stoffel W. Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci U S A. 2000;97:5895–900.
Marchesini N, Luberto C, Hannun YA. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem. 2003;278:13775–83.
Tani M, Hannun YA. Analysis of membrane topology of neutral sphingomyelinase 2. FEBS Lett. 2007;581:1323–8.
Wu BX, Clarke CJ, Matmati N, Montefusco D, Bartke N, Hannun YA. Identification of novel anionic phospholipid binding domains in neutral sphingomyelinase 2 with selective binding preference. J Biol Chem. 2011;286:22362–71.
Tani M, Hannun YA. Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues. Role of palmitoylation in subcellular localization. J Biol Chem. 2007;282:10047–56.
Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM, Hannun YA. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J Biol Chem. 2004;279:25101–11.
Milhas D, Clarke CJ, Idkowiak-Baldys J, Canals D, Hannun YA. Anterograde and retrograde transport of neutral sphingomyelinase-2 between the Golgi and the plasma membrane. Biochim Biophys Acta. 2010;1801:1361–74.
Levy M, Castillo SS, Goldkorn T. nSMase2 activation and trafficking are modulated by oxidative stress to induce apoptosis. Biochem Biophys Res Commun. 2006;344:900–5.
Levy M, Khan E, Careaga M, Goldkorn T. Neutral sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced apoptosis in lung cell death. Am J Physiol Lung Cell Mol Physiol. 2009;297:L125–33.
Filosto S, Castillo S, Danielson A, Franzi L, Khan E, Kenyon N, Last J, Pinkerton K, Tuder R, Goldkorn T. Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury. Am J Respir Cell Mol Biol. 2011;44:350–60.
Clement AB, Gamerdinger M, Tamboli IY, Lutjohann D, Walter J, Greeve I, Gimpl G, Behl C. Adaptation of neuronal cells to chronic oxidative stress is associated with altered cholesterol and sphingolipid homeostasis and lysosomal function. J Neurochem. 2009;111:669–82.
Chaube R, Kallakunta VM, Espey MG, McLarty R, Faccenda A, Ananvoranich S, Mutus B. Endoplasmic reticulum stress-mediated inhibition of NSMase2 elevates plasma membrane cholesterol and attenuates NO production in endothelial cells. Biochim Biophys Acta. 2012;1821:313–23.
De Palma C Meacci E Perrotta C Bruni P Clementi E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: a novel pathway relevant to the pathophysiology of endothelium. Arterioscler Thromb Vasc Biol. 2006;26:99–105.
Won JS, Im YB, Khan M, Singh AK, Singh I. The role of neutral sphingomyelinase produced ceramide in lipopolysaccharide-mediated expression of inducible nitric oxide synthase. J Neurochem. 2004;88:583–93.
Kucuksayan E, Konuk EK, Demir N, Mutus B, Aslan M. Neutral sphingomyelinase inhibition decreases ER stress-mediated apoptosis and inducible nitric oxide synthase in retinal pigment epithelial cells. Free Radic Biol Med. 2014;72:113–23.
Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008;111:4716–22.
Ito H, Murakami M, Furuhata A, Gao S, Yoshida K, Sobue S, Hagiwara K, Takagi A, Kojima T, Suzuki M, Banno Y, Tanaka K, Tamiya-Koizumi K, Kyogashima M, Nozawa Y, Murate T. Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin. Biochim Biophys Acta. 2009;1789:681–90.
Goswami R, Ahmed M, Kilkus J, Han T, Dawson SA, Dawson G. Differential regulation of ceramide in lipid-rich microdomains (rafts): antagonistic role of palmitoyl:protein thioesterase and neutral sphingomyelinase 2. J Neurosci Res. 2005;81:208–17.
Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, Kraveka JM, Khavandgar Z, Murshed M, Cevik MO, Ogretmen B. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther. 2012;11:1092–102.
Park B, Lee YM, Kim JS, Her Y, Kang JH, Oh SH, Kim HM. Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells. BMC Complement Altern Med. 2013;13:194.
Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem. 1997;272:16281–7.
Okamoto Y, Obeid LM, Hannun YA. Bcl-xL interrupts oxidative activation of neutral sphingomyelinase. FEBS Lett. 2002;530:104–8.
Clarke CJ, Mediwala K, Jenkins RW, Sutton CA, Tholanikunnel BG, Hannun YA. Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem. 2011;286:21565–76.
Ito H, Tanaka K, Hagiwara K, Kobayashi M, Hoshikawa A, Mizutani N, Takagi A, Kojima T, Sobue S, Ichihara M, Suzuki M, Tamiya-Koizumi K, Nakamura M, Banno Y, Nozawa Y, Murate T. Transcriptional regulation of neutral sphingomyelinase 2 in all-trans retinoic acid-treated human breast cancer cell line, MCF-7. J Biochem. 2012;151:599–610.
Ahn KH, Kim SK, Choi JM, Jung SY, Won JH, Back MJ, Fu Z, Jang JM, Ha HC, Kim DK. Identification of Heat Shock Protein 60 as a regulator of neutral sphingomyelinase 2 and its role in dopamine uptake. PloS One. 2013;8:e67216.
Clarke CJ, Truong TG, Hannun YA. Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2. J Biol Chem. 2007;282:1384–96.
Tellier E, Negre-Salvayre A, Bocquet B, Itohara S, Hannun YA, Salvayre R, Auge N. Role for furin in tumor necrosis factor alpha-induced activation of the matrix metalloproteinase/sphingolipid mitogenic pathway. Mol Cell Biol. 2007;27:2997–3007.
Barth BM, Gustafson SJ, Kuhn TB. Neutral sphingomyelinase activation precedes NADPH oxidase-dependent damage in neurons exposed to the proinflammatory cytokine tumor necrosis factor-alpha. J Neurosci Res. 2012;90:229–42.
Philipp S, Puchert M, Adam-Klages S, Tchikov V, Winoto-Morbach S, Mathieu S, Deerberg A, Kolker L, Marchesini N, Kabelitz D, Hannun YA, Schütze S, Adam D. The Polycomb group protein EED couples TNF receptor 1 to neutral sphingomyelinase. Proc Natl Acad Sci U S A. 2010;107:1112–7.
Filosto S, Fry W, Knowlton AA, Goldkorn T. Neutral sphingomyelinase 2 (nSMase2) is a phosphoprotein regulated by calcineurin (PP2B). J Biol Chem. 2010;285:10213–22.
Filosto S, Ashfaq M, Chung S, Fry W, Goldkorn T. Neutral sphingomyelinase 2 activity and protein stability are modulated by phosphorylation of five conserved serines. J Biol Chem. 2012;287:514–22.
Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res. 2005;44:207–34.
Acknowledgements
BM research related to this chapter is supported by grants from Seeds4Hope and Natural Sciences and Engineering Research Council (NSERC).
Conflict of interest
No potential conflicts of interest are disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Sun, B., Mutus, B. (2015). Neutral Sphingomyelinase 2: Structure, Function, and Regulation with Emphasis on Nitric Oxide Involvement and Potential Implications for Cancer Therapy. In: Bonavida, B. (eds) Nitric Oxide and Cancer: Pathogenesis and Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-13611-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-13611-0_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-13610-3
Online ISBN: 978-3-319-13611-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)